AtriCure (NASDAQ:ATRC) Stock Rating Cut to Hold at Freedom Capital

Freedom Capital lowered shares of AtriCure (NASDAQ:ATRC) from a strong-buy rating to a hold rating in a report published on Friday morning,Zacks reports.

Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC raised their price target on shares of AtriCure from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, September 2nd. Zacks Research cut AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday, August 24th. UBS Group lowered their price target on AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Finally, Weiss Ratings upgraded AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. Seven equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $53.30.

AtriCure Trading Up 2.9%

Shares of ATRC opened at $55.14 on Friday. The firm’s 50-day moving average is $49.44 and its two-hundred day moving average is $36.38. The firm has a market capitalization of $2.80 billion, a P/E ratio of 262.58 and a beta of 1.24. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. AtriCure has a twelve month low of $25.36 and a twelve month high of $61.70.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The firm had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period last year, the business posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, research analysts predict that AtriCure will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Justin Noznesky sold 6,182 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total value of $239,861.60. Following the completion of the sale, the insider directly owned 100,219 shares in the company, valued at approximately $3,888,497.20. The trade was a 5.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Vinayak Doraiswamy sold 6,000 shares of the business’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total transaction of $233,280.00. Following the sale, the insider owned 86,511 shares of the company’s stock, valued at approximately $3,363,547.68. The trade was a 6.49% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 74,868 shares of company stock worth $3,317,897. 4.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AtriCure

Several institutional investors have recently modified their holdings of ATRC. Man Group plc bought a new position in AtriCure in the 2nd quarter worth about $684,000. Bank of America Corp DE boosted its stake in AtriCure by 13.7% during the 1st quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock valued at $21,927,000 after purchasing an additional 92,830 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in AtriCure during the second quarter worth about $699,000. WINTON GROUP Ltd acquired a new position in shares of AtriCure in the 2nd quarter worth approximately $1,002,000. Finally, Assenagon Asset Management S.A. acquired a new position in AtriCure in the second quarter worth approximately $1,744,000. Institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on developing and commercializing technologies for the treatment of atrial fibrillation (AF) and related cardiac conditions. Its products are used primarily in cardiac surgery and electrophysiology procedures to create surgical lesions that interrupt abnormal electrical signals in the heart.

The company’s portfolio includes the AtriCure Isolator Synergy ablation system, cryoablation products sold under the cryoICE brand, and the AtriClip system for the exclusion of the left atrial appendage, a potential source of blood clots in patients with AF.